 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 October 1996 | Volume 125 Issue 7 | Pages 605-613
Phase 3 clinical trials, which evaluate the effect that new interventions have on the clinical outcomes of particular relevance to the patient (such as death, loss of vision, or other major symptomatic event), often require many participants to be followed for a long time.There has recently been great interest in using surrogate end points, such as tumor shrinkage or changes in cholesterol level, blood pressure, CD4 cell count, or other laboratory measures, to reduce the cost and duration of clinical trials. In theory, for a surrogate end point to be an effective substitute for the clinical outcome, effects of the intervention on the surrogate must reliably predict the overall effect on the clinical outcome. In practice, this requirement frequently fails. Among several explanations for this failure is the possibility that the disease process could affect the clinical outcome through several causal pathways that are not mediated through the surrogate, with the intervention's effect on these pathways differing from its effect on the surrogate. Even more likely, the intervention might also affect the clinical outcome by unintended, unanticipated, and unrecognized mechanisms of action that operate independently of the disease process. We use examples from several disease areas to illustrate how surrogate end points have been misleading about the actual effects that treatments have on the health of patients.
Surrogate end points can be useful in phase 2 screening trials for identifying whether a new intervention is biologically active and for guiding decisions about whether the intervention is promising enough to justify a large definitive trial with clinically meaningful outcomes.In definitive phase 3 trials, except for rare circumstances in which the validity of the surrogate end point has already been rigorously established, the primary end point should be the true clinical outcome.
Author and Article Information
From the University of Washington, Seattle, Washington; and the University of Wisconsin-Madison, Medical School, Madison, Wisconsin.
PERSPECTIVE
Surrogate End Points in Clinical Trials: Are We Being Misled?
Acknowledgments: The authors thank Robert Temple, Curt Furberg, and the reviewers for providing valuable suggestions.
Grant Support: By research grants AI 29168 and CA 18332 from the National Institutes of Health.
Requests for Reprints: Thomas R. Fleming, PhD, Department of Biostatistics, Box 357232, University of Washington, Seattle, WA 98195-7232.
Current Author Addresses: Dr. Fleming: Department of Biostatistics, Box 357232, University of Washington, Seattle, WA 98195-7232.
This article has been cited by other articles:
|
|
 |
|
  C. E. Ventetuolo, R. L. Benza, A. J. Peacock, R. T. Zamanian, D. B. Badesch, and S. M. Kawut Surrogate and Combined End Points in Pulmonary Arterial Hypertension Proceedings of the ATS, July 15, 2008; 5(5): 617 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Petkau, S. Reingold, U Held, G. Cutter, T. Fleming, M. Hughes, D. Miller, H. McFarland, and J. Wolinsky Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses Multiple Sclerosis, July 1, 2008; 14(6): 770 - 778. [Abstract] [PDF]
|
|
|
|
 |
|
 M. N Lassere The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints Statistical Methods in Medical Research, June 1, 2008; 17(3): 303 - 340. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Tonelli Randomized Trials in Hemodialysis Patients: Time to Step Up to the Plate JAMA, May 14, 2008; 299(18): 2205 - 2207. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Sargent and D. F. Hayes Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters? J. Clin. Oncol., April 20, 2008; 26(12): 1922 - 1923. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Italiano, C. Massard, R. Bahleda, A.-L. Vataire, E. Deutsch, N. Magne, J.-P. Pignon, G. Vassal, J.-P. Armand, and J.-C. Soria Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy Ann. Onc., April 1, 2008; 19(4): 787 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Chan, S. M. Ueda, V. E. Sugiyama, C. D. Stave, J. Y. Shin, B. J. Monk, B. I. Sikic, K. Osann, and D. S. Kapp Analysis of Phase II Studies on Targeted Agents and Subsequent Phase III Trials: What Are the Predictors for Success? J. Clin. Oncol., March 20, 2008; 26(9): 1511 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Goldman, M. LeBlanc, and J. Crowley Interim futility analysis with intermediate endpoints Clinical Trials, February 1, 2008; 5(1): 14 - 22. [Abstract] [PDF]
|
|
|
|
 |
|
 R. A. Harrington, V. Hasselblad, and R. M. Califf Defining and utilizing surrogates in the evaluation of coronary stents: what do we really want and need to know? J. Am. Coll. Cardiol., January 1, 2008; 51(1): 33 - 36. [Full Text] [PDF]
|
|
|
|
|
|
A. Pryseley, A. Tilahun, A. Alonso, and G. Molenberghs Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints Clinical Trials, December 1, 2007; 4(6): 587 - 597. [Abstract] [PDF]
|
|
|
|
|
|
M. Buyse, T. Burzykowski, K. Carroll, S. Michiels, D. J. Sargent, L. L. Miller, G. L. Elfring, J.-P. Pignon, and P. Piedbois Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5218 - 5224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.P. MacKinnon, C.M. Lockwood, C.H. Brown, W. Wang, and J.M. Hoffman The intermediate endpoint effect in logistic and probit regression Clinical Trials, October 1, 2007; 4(5): 499 - 513. [Abstract] [PDF]
|
|
|
|
 |
|
 D. B Mark Percutaneous coronary revascularisation: is it ever worth what it costs? Heart, October 1, 2007; 93(10): 1161 - 1163. [Full Text] [PDF]
|
|
|
|
|
|
Z. A. Aziz United Kingdom Cystic Fibrosis Gene Therapy Consortium Multidose Trial: The Proposed Use of Computed Tomography Proceedings of the ATS, August 1, 2007; 4(4): 355 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Schuster The Opportunities and Challenges of Developing Imaging Biomarkers to Study Lung Function and Disease Am. J. Respir. Crit. Care Med., August 1, 2007; 176(3): 224 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfeffer and the TREAT Executive Committee An Ongoing Study of Anemia Correction in Chronic Kidney Disease N. Engl. J. Med., March 1, 2007; 356(9): 959 - 961. [Full Text] [PDF]
|
|
|
|
 |
|
 H. I. Scher, M. Warren, and G. Heller The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer Clin. Cancer Res., March 1, 2007; 13(5): 1488 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Rha and J. L. Saver The Impact of Recanalization on Ischemic Stroke Outcome: A Meta-Analysis Stroke, March 1, 2007; 38(3): 967 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z A Aziz, J C Davies, E W Alton, A U Wells, D M Geddes, and D M Hansell Computed tomography and cystic fibrosis: promises and problems Thorax, February 1, 2007; 62(2): 181 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Califf, R. A. Harrington, L. K. Madre, E. D. Peterson, D. Roth, and K. A. Schulman Curbing The Cardiovascular Disease Epidemic: Aligning Industry, Government, Payers, And Academics Health Aff., January 1, 2007; 26(1): 62 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schatzkin Can Biomarkers Help Us Understand the Nutritional and Lifestyle Factors Important in Cancer Prognosis? J. Nutr., January 1, 2007; 137(1): 249S - 252S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Weber and R. Figlin Monitoring Cancer Treatment with PET/CT: Does It Make a Difference? J. Nucl. Med., January 1, 2007; 48(1_suppl): 36S - 44S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Appel A Primer on the Design, Conduct, and Interpretation of Clinical Trials Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1360 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ott, W. A. Weber, F. Lordick, K. Becker, R. Busch, K. Herrmann, H. Wieder, U. Fink, M. Schwaiger, and J.-R. Siewert Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction J. Clin. Oncol., October 10, 2006; 24(29): 4692 - 4698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Lang Documenting research in scientific articles: guidelines for authors: reporting research designs and activities. Chest, October 1, 2006; 130(4): 1263 - 1268. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. F. Habbema, S. Y. G. L. Tan, and K. A. Cronin Chapter 14: Impact of Mammography on U.S. Breast Cancer Mortality, 1975-2000: Are Intermediate Outcome Measures Informative? J Natl Cancer Inst Monographs, October 1, 2006; 2006(36): 105 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hilbrich and P. Sleight Progress and problems for randomized clinical trials: from streptomycin to the era of megatrials Eur. Heart J., September 2, 2006; 27(18): 2158 - 2164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Granger and J. J.V. McMurray Using Measures of Disease Progression to Determine Therapeutic Effect: A Sirens' Song J. Am. Coll. Cardiol., August 1, 2006; 48(3): 434 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Jaffe Measures of Response: RECIST, WHO, and New Alternatives J. Clin. Oncol., July 10, 2006; 24(20): 3245 - 3251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Tardif, T. Heinonen, D. Orloff, and P. Libby Vascular Biomarkers and Surrogates in Cardiovascular Disease Circulation, June 27, 2006; 113(25): 2936 - 2942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. HAK, A. W HOES, J. NORDIN, and K. L NICHOL Benefits of influenza vaccine in US elderly--appreciating issues of confounding bias and precision Int. J. Epidemiol., June 1, 2006; 35(3): 800 - 802. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gill and D. Sargent End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? Oncologist, June 1, 2006; 11(6): 624 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. F. Boyd, L. J. Martin, Q. Li, L. Sun, A. M. Chiarelli, G. Hislop, M. J. Yaffe, and S. Minkin Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Saver Does the Merci Retriever Work?: For Stroke, May 1, 2006; 37(5): 1340 - 1341. [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Baker Surrogate endpoints: wishful thinking or reality? J Natl Cancer Inst, April 19, 2006; 98(8): 502 - 503. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lauer Cashing in on Shame: How the Popular "Tradition vs. Modernity" Dualism Contributes to the "HIV/AIDS Crisis" in Africa Review of Radical Political Economics, March 1, 2006; 38(1): 90 - 138. [Abstract] [PDF]
|
|
|
|
|
|
W. A. Ray and C. M. Stein Reform of Drug Regulation -- Beyond an Independent Drug-Safety Board N. Engl. J. Med., January 12, 2006; 354(2): 194 - 201. [Full Text] [PDF]
|
|
|
|
|
|
S. Teramukai, H. Nishiyama, Y. Matsui, O. Ogawa, and M. Fukushima Evaluation for Surrogacy of End Points by Using Data from Observational Studies: Tumor Downstaging for Evaluating Neoadjuvant Chemotherapy in Invasive Bladder Cancer Clin. Cancer Res., January 1, 2006; 12(1): 139 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H F McFarland and S C Reingold The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic eraa Multiple Sclerosis, December 1, 2005; 11(6): 669 - 676. [Abstract] [PDF]
|
|
|
|
|
|
D. J. Sargent, H. S. Wieand, D. G. Haller, R. Gray, J. K. Benedetti, M. Buyse, R. Labianca, J. F. Seitz, C. J. O'Callaghan, G. Francini, et al. Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials J. Clin. Oncol., December 1, 2005; 23(34): 8664 - 8670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Johnson and G. Raghu Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures Eur. Respir. J., November 1, 2005; 26(5): 755 - 758. [Full Text] [PDF]
|
|
|
|
|
|
A. S. Brody, H. Sucharew, J. D. Campbell, S. P. Millard, P. L. Molina, J. S. Klein, and J. Quan Computed Tomography Correlates with Pulmonary Exacerbations in Children with Cystic Fibrosis Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1128 - 1132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Thabut and D. Logeart Thrombolysis for Pulmonary Embolism in Patients With Right Ventricular Dysfunction: Con Arch Intern Med, October 24, 2005; 165(19): 2200 - 2203. [Full Text] [PDF]
|
|
|
|
|
|
L. Collette, T. Burzykowski, K. J. Carroll, D. Newling, T. Morris, and F. H. Schroder Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals J. Clin. Oncol., September 1, 2005; 23(25): 6139 - 6148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dibra, A. Kastrati, J. Mehilli, J. Pache, H. Schuhlen, N. von Beckerath, K. Ulm, R. Wessely, J. Dirschinger, A. Schomig, et al. Paclitaxel-Eluting or Sirolimus-Eluting Stents to Prevent Restenosis in Diabetic Patients N. Engl. J. Med., August 18, 2005; 353(7): 663 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bruzzi, L. Del Mastro, M. P. Sormani, L. Bastholt, M. Danova, C. Focan, G. Fountzilas, J. Paul, R. Rosso, and M. Venturini Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients J. Clin. Oncol., August 1, 2005; 23(22): 5117 - 5125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. A. Ioannidis Contradicted and Initially Stronger Effects in Highly Cited Clinical Research JAMA, July 13, 2005; 294(2): 218 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Gilbert and Y. Sun Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation Biostat., July 1, 2005; 6(3): 374 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. B. Rothschild, N. M.P. King, F. M. Muggia, I. Sekine, T. Tamura, M. J. Miller, E. Horstmann, E. J. Emanuel, C. Grady, R. Kurzrock, et al. Phase 1 Clinical Trials in Oncology N. Engl. J. Med., June 9, 2005; 352(23): 2451 - 2453. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tahara, A. Ohtsu, S. Hironaka, N. Boku, S. Ishikura, Y. Miyata, T. Ogino, and S. Yoshida Clinical Impact of Criteria for Complete Response (CR) of Primary Site to Treatment of Esophageal Cancer Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 316 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Grimes and K. F. Schulz Surrogate End Points in Clinical Research: Hazardous to Your Health Obstet. Gynecol., May 1, 2005; 105(5): 1114 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ravina, D. Eidelberg, J. E. Ahlskog, R. L. Albin, D. J. Brooks, M. Carbon, V. Dhawan, A. Feigin, S. Fahn, M. Guttman, et al. The role of radiotracer imaging in Parkinson disease Neurology, January 25, 2005; 64(2): 208 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Fleming Surrogate Endpoints And FDA's Accelerated Approval Process Health Aff., January 1, 2005; 24(1): 67 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Gralla Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life Oncologist, December 1, 2004; 9(suppl_6): 14 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bloomfield and D. W. Noble Editorial III: Corticosteroids for septic shock--a standard of care? Br. J. Anaesth., August 1, 2004; 93(2): 178 - 180. [Full Text] [PDF]
|
|
|
|
 |
|
 R.B. D'Agostino Sr. and J.M. Massaro New Developments in Medical Clinical Trials J. Dent. Res., July 1, 2004; 83(suppl_1): C18 - C24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Wyse and B. J. Gersh Atrial Fibrillation: A Perspective: Thinking Inside and Outside the Box Circulation, June 29, 2004; 109(25): 3089 - 3095. [Full Text] [PDF]
|
|
|
|
|
|
M. Wong, L. Staszewsky, R. Latini, S. Barlera, R. Glazer, N. Aknay, A. Hester, I. Anand, and J. N. Cohn Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data J. Am. Coll. Cardiol., June 2, 2004; 43(11): 2022 - 2027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.M. Kawut and H.I. Palevsky New answers raise new questions in pulmonary arterial hypertension Eur. Respir. J., June 1, 2004; 23(6): 799 - 801. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, M. Thamer, K. Stefanik, and D. J. Cotter Does dose matter? Nephrol. Dial. Transplant., June 1, 2004; 19(6): 1658 - 1658. [Full Text] [PDF]
|
|
|
|
|
|
G. Molenberghs, T. Burzykowski, A. Alonso, and M. Buyse A perspective on surrogate endpoints in controlled clinical trials |
Article
